Safeguarding Women from Chemical Abortion Act

Legislative bill overview

S 4066 would rescind the FDA's approval of mifepristone (the abortion pill) by deeming the existing application withdrawn, effectively removing it from the market. The bill would also create a federal tort allowing women to sue for damages allegedly caused by chemical abortion drugs, establishing new legal liability for providers and manufacturers.

Why is this important

This bill directly addresses one of the most contentious healthcare and constitutional issues in American politics. If enacted, it would eliminate access to medication abortion nationwide, overriding state laws that protect or allow the procedure, and would create new litigation pathways that could significantly impact reproductive healthcare providers and pharmaceutical companies.

Potential points of contention

• Constitutional questions: Legal challenges would likely arise regarding federal authority to rescind FDA approval, separation of powers, and potential conflicts with state laws protecting abortion access
• Definition and causation in tort liability: The bill's language on what constitutes "harm" from chemical abortion drugs is undefined, creating uncertainty about what medical outcomes would be actionable and who bears liability
• Practical enforcement: Establishing causation between mifepristone use and alleged harm raises complex medical and legal evidentiary questions, and the bill doesn't specify statute of limitations or damages caps